Results 31 to 40 of about 21,820 (216)
Resistance to ceftazidime–avibactam and underlying mechanisms
Journal of Global Antimicrobial Resistance, 2020 Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic β-lactamase inhibitor combination. Although the combination has been available clinically for only a few years, cases of resistance to CAZ-AVI have already been reported.In the present review, we summarize the distribution of CAZ-AVI-resistant strains and the possible resistance mechanisms.There are ...
Yuhang Wang, Jin Wang, Rui Wang, Yun Cai
openaire +3 more sources
Antibiotics, 2020 Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant Enterobacterales (CRE) is very limited.
Antonio Vena +19 more
doaj +1 more source
, 2023 Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria.
Nadia Marascio (3819316) +13 more
core +1 more source
The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study
Infectious Diseases and Therapy, 2023 Introduction Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and ...
Alex Soriano +22 more
doaj +1 more source
İstanbul Tıp Fakültesi Dergisi, 2022 Objective: Infections caused by multi drug-resistant Gram-negative bacilli are increasingly reported worldwide. Ceftazidime-avibactam is a novel antibiotic combination that presents good activity against carbapenem-resistant Enterobacterales members and ...
Tuğrul Hoşbul +5 more
doaj +1 more source
International Journal of Infectious Diseases, 2017 Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom +9 more
doaj +1 more source
Frontiers in Microbiology, 2022 Ceftazidime-avibactam is one of the last resort antimicrobial agents for the treatment of carbapenem-resistant, Gram-negative bacteria. Metallo-β-lactamase-producing bacteria are considered to be ceftazidime-avibactam resistant. Here, we evaluated a semi-
Michaela Simon +16 more
doaj +1 more source
Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases. [PDF]
, 2020 Class D β-lactamases exhibit very heterogeneous hydrolysis activity spectra against the various types of clinically useful β-lactams. Similarly, and according to the available data, their sensitivities to inactivation by avibactam can vary by a factor of
Bouillenne, Fabrice +15 more
core +1 more source
Brazilian Journal of Infectious Diseases, 2021 The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to
James A. Karlowsky +8 more
doaj +1 more source
Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
WIREs Mechanisms of Disease, 2022 AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal
Luying Xiong +7 more
openaire +2 more sources